are winners!

Top News

Planegg/Martinsried (13.01.2021) - Medigene AG (Medigene, FSE: MDG1, Prime Standard), a clinical stage immuno-oncology company focusing on the development of T cell immunotherapies, was granted patents around certain technologies in significant territories including both the USA and Europe. Patent applications in further jurisdictions are pending. TCR library (US10,858,760)  This US patent (a member of the same patent family was granted in Europe in 2019, EP3303591), covers Medigene's T cell receptor (TCR) building block library that enables rapid reconstruction and testing of newly discovered human TCR ... [ more ]